Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.
CANFIELD, Ohio (MyValleyTributes) – Domenico Fabiilli, 99, passed away peacefully on Sunday February 23, 2025 at The Inn at Old Saybrook in Columbiana. Domenico was born in 1925 in Pacentro, Abruzzo, ...
Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by ...
Goldman Sachs analyst Salveen Richter initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target a Summit’s lead ...
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment ...
Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1, a self-developed and ...
Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication ...
Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This ...
NEW MIDDLETOWN, Ohio (MyValleyTributes) – On Friday, February 22, 2025, Thomas Frederick Geidner, age 82, passed away. He was ...
AstraZeneca signed a $1.92 billion deal with China’s CSPC Pharmaceutical Group (CSPC) last year to develop cardiovascular medication, and Merck has a $2 billion agreement with China’s Hansoh ...
Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good morning and welcome to Summit Therapeutics Fourth Quarter and Year End 2024 Earnings and Update Call. All participants will be in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback